- 专利标题: Fused Pentacyclic Imidazole Derivatives
-
申请号: US15513357申请日: 2015-10-02
-
公开(公告)号: US20170305932A1公开(公告)日: 2017-10-26
- 发明人: Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
- 申请人: UCB Biopharma SPRL , Sanofi
- 优先权: EP14290299.8 20141003; EP15162641.3 20150407; EP15171036.5 20150608
- 国际申请: PCT/EP2015/072868 WO 20151002
- 主分类号: C07D519/00
- IPC分类号: C07D519/00 ; C07D495/18 ; C07D487/18 ; C07D491/18 ; C07F7/18 ; C07D513/18
摘要:
A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
公开/授权文献
- US10202405B2 Fused pentacyclic imidazole derivatives 公开/授权日:2019-02-12
信息查询